Unfortunately, because ADAM10 and/or ADAM17 have more than 80 other substrates, the cleavages of which yielding to pathological situations such as cancer and chronic inflammation [9], one should stay very cautious regarding the use of acute pharmacological activation of α-secretases and to rather envision stimulating these proteases via the mild, safe and regular consumption of natural compounds that would reduce the amyloid load on a long term basis and could thereby represent a valuable therapeutic alternative for AD treatment [26]. The gene discussed is ADAM17; the disease is Alzheimer disease.